Metastatic pancreatic neuroendocrine tumors (pNET): Placing current findings into perspective

Cancer Treatment Reviews

Volumn 39, Issue 1, 2013, Pages 3-9

  Phan, Alexandria T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Everolimus; Pancreatic neuroendocrine tumors; PNET; Sunitinib

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; OCTREOTIDE; PAZOPANIB; PLACEBO; SOMATOSTATIN DERIVATIVE; SORAFENIB; SUNITINIB;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC ACTIVITY; ASTHENIA; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL PRACTICE; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG RECEPTOR BINDING; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUTROPENIA; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RASH; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

HUMANS; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

EID: 84869079653     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.02.010     Document Type: Review

References (46)

1. Strosberg J.R., Nasir A., Hodul P., Kvols L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res 2008, 2:113-125.
2. Clark O.H., Benson A.B., Berlin J.D., et al. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Comprehensive Cancer Netw 2010, 7:712-747.
3. Klimstra D.S., Modlin I.R., Coppola D., Lloyd R.V., Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010, 39:707-712.
4. Yao J.C., Hassan M., Phan A., et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26:3063-3072.
5. Halfdanarson T.R., Rubin J., Farnell M.B., Grant C.S., Petersen G.M. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Related Cancer 2008, 15:409-427.
6. Sandostatin LAR® depot (octreotide acetate for injectable suspension) [prescribing information]. East Hanover, NJ: Novartis Pharmaceutical Corporation; January 2010.
7. Oberg K. Neuroendocrine tumours. Treatment Strategies. Oncol 2011, 2:1-8.
8. Basu B., Sirohi B., Corrie P. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr Related Cancer 2010, 17:R75-90.
9. Modlin I.M., Oberg K., Chung D.C., et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008, 9:61-72.
10. Metz D.C., Jensen R.T. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008, 135:1469-1492.
11. Murray-Lyon I.M., Eddleston A.L., Williams R., et al. Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet 1968, 2:895-898.
12. Taylor S.G., Schwartz T.B., Zannini J.J., Ryan W.G. Streptozotocin therapy for metastatic insulinoma. Arch Intern Med 1970, 126:654-657.
13. Moertel C.G., Lefkopoulo M., Lipsitz S., Hahn R.G., Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992, 326:519-523.
14. Delaunoit T., Van den Eynde M., Borbath I., et al. Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story?. Acta Gastroenterol Belg 2009, 72:49-53.
15. Kulke M.H., Stuart K., Enzinger P.C., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006, 24:401-406.
16. Strosberg J.R., Fine R.L., Choi J., et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011, 117:268-275.
17. Kulke M.H., Siu L.L., Tepper J.E., et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. J Clin Oncol 2011, 29:934-943.
18. Tokunaga C., Yoshino K., Yonezawa K. MTOR integrates amino acid- and energy-sensing pathways. Biochem Biophys Res Commun 2004, 313:443-446.
19. Rosner M., Hanneder M., Siegel N., Valli A., Fuchs C., Hengstschlager M. The mTOR pathway and its role in human genetic diseases. Mutat Res 2008, 659:284-292.
20. Jiao Y., Shi C., Edil B.H., et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011, 331:1199-1203.
21. Houghton P.J. Everolimus. Clin Cancer Res 2010, 16:1368-1372.
22. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
23. Afinitor® (everolimus) tablets for oral administration [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2011.
24. Yao J.C., Phan A.T., Chang D.Z., et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008, 26:4311-4318.
25. Yao J.C., Shah M.H., Ito T., et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:514-523.
26. Phan A.T., Wang L., Xie K., et al. Association of VEGF expression with poor prognosis among patients with low-grade neuroendocrine carcinoma. J Clin Oncol 2006, 24(Suppl. 185). [abstract].
27. Yao J.C., Phan A., Hoff P.M., et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008, 26:1316-1323.
28. Hobday T.J., Rubin J., Holen K., et al. MCO44h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study [abstract]. J Clin Oncol 2007, 25:4504.
29. Phan A.T., Yao J.C., Fogelman D.R., et al. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 2010, 28(Suppl. 15). [abstract].
30. Kulke M.H., Lenz H.J., Meropol N.J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26:3403-3410.
31. Mena A.C., Pulido E.G., Guillen-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs 2010, 21(suppl 1):S3-11.
32. SUTENT® (sunitinib malate) capsules, oral [prescribing information]. New York, NY: Pfizer Inc; May 2011.
33. Raymond E., Dahan L., Raoul J.L., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:501-513.
34. Shah M.H., Lombard-Bohas C., Ito T., et al. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial. J Clin Oncol 2011, 29. [abstract].
35. Strosberg JR, Lincy J, Winkler RE, Wolin EM. Everolimus in patients with advanced pancreatic neuroendocrine tumors: updated results of a randomized, double-blind, placebo-controlled, multicenter, phase III trial (RADIANT-3). Presented at: 47th Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2011; Chicago, Illinois.
36. Kulke M.H., Bergsland E.K., Yao J.C. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009, 360:195-197.
37. Leibiger I.B., Leibiger B., Moede T., Berggren P.O. Exocytosis of insulin promotes insulin gene transcription via the insulin receptor/PI-3 kinase/p70 s6 kinase and CaM kinase pathways. Mol Cell 1998, 1:933-938.
38. Fuhrer D.K., Kobayashi M., Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. DiabetObesMetab 2001, 3:393-402.
39. Di Paolo S., Teutonico A., Leogrande D., Capobianco C., Schena P.F. Schena PF. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes?. J Am Soc Nephrol 2006, 17:2236-2244.
40. Sutent® (sunitinib malate) [prescribing information]. New York, NY: Pfizer, Inc.; November 2008.
41. Jensen R.T., Delle F.G. Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 2011, 364:564-565.
42. Janson E.T., Sorbye H., Welin S., et al. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol 2010, 49:740-756.
43. Oberg K., Akerstrom G., Rindi G., Jelic S. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(suppl 5):v223-v227.
44. Maton P.N. Use of octreotide acetate for control of symptoms in patients with islet cell tumors. World J Surg 1993, 17:504-510.
45. Wymenga A.N., Eriksson B., Salmela P.I., et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999, 17:1111.
46. Ng C.S., Charnsangavej C., Wei W., Yao J.C. Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. AJR Am J Roentgenol 2011, 196:569-576.